ES2067240T3 - Derivados de (2-imidazolin-2-ilamino) quinoxalina y metodos para su uso. - Google Patents

Derivados de (2-imidazolin-2-ilamino) quinoxalina y metodos para su uso.

Info

Publication number
ES2067240T3
ES2067240T3 ES91913885T ES91913885T ES2067240T3 ES 2067240 T3 ES2067240 T3 ES 2067240T3 ES 91913885 T ES91913885 T ES 91913885T ES 91913885 T ES91913885 T ES 91913885T ES 2067240 T3 ES2067240 T3 ES 2067240T3
Authority
ES
Spain
Prior art keywords
group
carbon
atoms
imidazolin
ilamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913885T
Other languages
English (en)
Inventor
Charles Gluchowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2067240T3 publication Critical patent/ES2067240T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO SELECCIONADO DEL GRUPO QUE CONSISTE AQUELLOS QUE TIENEN LA FORMULA (I) Y LAS SALES DE ADICION ACIDAS FARMACEUTICAMENTE ACEPTABLES DEL MISMO, EN DONDE R1 Y R4 SE SELECCIONAN INDEPENDIENTEMENTE DEL GRUPO QUE CONSISTE EN RADICALES H Y ALQUILO QUE TIENEN DE 1 A 4 ATOMOS DE CARBONO; LOS R2 SON CADA UNO RADICALES H O ALQUILO QUE TIENEN DE 1 A 4 ATOMOS DE CARBONO, O JUNTOS, SON OXO; LOS R3 SON CADA UNO RADICALES H O ALQUILO QUE TIENE DE 1 A 4 ATOMOS DE CARBONO O SON, JUNTOS, OXO, SIEMPRE Y CUANDO A LOS R2 O LOS R3 SEAN RADICALES ALQUILO; EL GRUPO 2-IMIDAZOLIN-2-ILAMINO PUEDE SER CUALQUIERA DE LAS POSICIONES 5, 6, 7 U 8 DEL NUCLEO DE QUINOXALINA; Y R5, R6 Y R7 SE ENCUENTRAN CADA UNO EN UNA DE LAS POSICIONES 5, 6, 7, U 8 RESTANTES DEL NUCLEO DE QUINOXALINA Y SE SELECCIONA INDEPENDIENTEMENTE DEL GRUPO QUE CONSISTE EN RADICALES CL, BR, H Y ALQUILO QUE TIENEN DE 1 A 3 ATOMOS DE CARBONO. TALES COMPUESTOS, CUANDO SE ADMINISTRAN A UN MAMIFERO, PROPORCIONAN UNOS EFECTOS TERAPEUTICOS DESEADOS,TAL COMO UNA ALTERACION DE LA VELOCIDAD DE TRANSPORTE DE FLUIDOS EN EL APARATO GASTROINTESTINAL, LA REDUCCION DE LA PRESION INTRAOCULAR Y UN AUMENTO DEL FLUJO DE FLUIDOS RENAL.
ES91913885T 1990-07-31 1991-07-22 Derivados de (2-imidazolin-2-ilamino) quinoxalina y metodos para su uso. Expired - Lifetime ES2067240T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/560,776 US5112822A (en) 1989-10-12 1990-07-31 (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same

Publications (1)

Publication Number Publication Date
ES2067240T3 true ES2067240T3 (es) 1995-03-16

Family

ID=24239318

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913885T Expired - Lifetime ES2067240T3 (es) 1990-07-31 1991-07-22 Derivados de (2-imidazolin-2-ilamino) quinoxalina y metodos para su uso.

Country Status (19)

Country Link
US (1) US5112822A (es)
EP (1) EP0549594B1 (es)
JP (1) JP3220454B2 (es)
AT (1) ATE118003T1 (es)
AU (1) AU643316B2 (es)
CA (1) CA2087606C (es)
DE (1) DE69107215T2 (es)
DK (1) DK0549594T3 (es)
ES (1) ES2067240T3 (es)
FI (1) FI930364A (es)
GR (1) GR3015914T3 (es)
HU (1) HUT64331A (es)
IE (1) IE70301B1 (es)
IL (1) IL98735A (es)
NO (1) NO930325L (es)
NZ (2) NZ238874A (es)
PT (1) PT98523A (es)
WO (1) WO1992002515A1 (es)
ZA (1) ZA915960B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
EP1285657A3 (en) * 1993-10-13 2003-08-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU677513B2 (en) * 1994-02-08 1997-04-24 Alcon Laboratories, Inc. Novel process for preparation of clonidine derivatives
CA2220517A1 (en) * 1995-05-12 1996-11-14 Allergan Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
US6087361A (en) * 1995-05-12 2000-07-11 Allergan Sales, Inc. Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects
AU744018B2 (en) * 1995-05-12 2002-02-14 Allergan, Inc. Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
WO2005014046A2 (en) * 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
CN101355876B (zh) 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
DK2552449T3 (en) 2010-03-26 2017-06-19 Galderma Res & Dev COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
KR20150058551A (ko) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
CA2814952C (en) 2010-10-21 2016-05-10 Galderma S.A. Brimonidine gel compositions and methods of use
KR200493684Y1 (ko) * 2019-08-21 2021-05-17 김석균 튜브 배출 보조 클립
CN112403513A (zh) * 2020-11-03 2021-02-26 桂林理工大学 一种三乙烯二胺衍生物手性催化剂及其合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

Also Published As

Publication number Publication date
NZ328001A (en) 2000-07-28
EP0549594A4 (en) 1993-04-16
CA2087606A1 (en) 1992-02-01
JPH05509097A (ja) 1993-12-16
CA2087606C (en) 2001-10-23
GR3015914T3 (en) 1995-07-31
IE70301B1 (en) 1996-11-13
IL98735A (en) 1998-01-04
DK0549594T3 (da) 1995-04-10
WO1992002515A1 (en) 1992-02-20
IL98735A0 (en) 1992-07-15
US5112822A (en) 1992-05-12
EP0549594B1 (en) 1995-02-01
JP3220454B2 (ja) 2001-10-22
HUT64331A (en) 1993-12-28
IE912676A1 (en) 1992-02-12
DE69107215D1 (de) 1995-03-16
AU8289491A (en) 1992-03-02
NZ238874A (en) 1994-01-26
NO930325D0 (no) 1993-01-29
FI930364A (fi) 1993-03-24
AU643316B2 (en) 1993-11-11
DE69107215T2 (de) 1995-05-24
EP0549594A1 (en) 1993-07-07
FI930364A0 (fi) 1993-01-28
ZA915960B (en) 1992-03-25
NO930325L (no) 1993-03-29
PT98523A (pt) 1992-06-30
ATE118003T1 (de) 1995-02-15

Similar Documents

Publication Publication Date Title
ES2067240T3 (es) Derivados de (2-imidazolin-2-ilamino) quinoxalina y metodos para su uso.
ES2063289T3 (es) (2-imidazolin-2-ilamino) tetrahidroquinoxalinas y metodos para usarlas.
AR039189A1 (es) Compuesto de pirrolopiridazina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
ES2076009T3 (es) Nuevos inhibidores de n-miristoil-transferasa, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
MX9302088A (es) Derivados de alfa-tiocarbonilo y alfa-halocarbonilo, proceso para su preparacion y composicion farmaceutica que los comprende.
DK152090D0 (da) Piperidylsubstituerede indolderivater
DK0587193T3 (da) 1,2-ethandiolderivat og salt deraf, fremgangsmåde til fremstilling af samme og cerebralfunktionsforbedrende middel omfattende samme
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
ES2109988T3 (es) Derivados cefalosporinicos.
AR039319A1 (es) Imidazolinilmetil aralquilsulfonamidas
GB1141936A (en) Improvements in or relating to benzimidazole derivatives
YU140391A (sh) 6-supstituisani-heksahidrobenz (cd)-indoli
DE60104435D1 (en) 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel
SE8203053L (sv) Cysteinderivat i form av disulfid
YU140491A (sh) 6-supstituisani-tetrahidrobenz(c,d) indoli
ATE48130T1 (de) Alpha-aryl-alpha-pyridylalkanoicsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzung.
SE8107806L (sv) N-substituerade iminodiettiksyror
ES2091558T3 (es) Derivados benzoato sustituidos.
ES383587A1 (es) Un procedimiento para producir nuevos derivados de 1,4-ben-zodiazepina sustituidos en posicion 1.
ES367589A1 (es) Un procedimiento para la preparacion de un 2,3,5,9 b-tetra-hidro-5h-imidazo (2,i-a) isoindol-5-ol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 549594

Country of ref document: ES